Experience in using noliprel and its combination with hormonal replacement therapy in women with postmenopausal hypertensive disease
| Autor: | O. O. Bolshakova, U. V. Voronina, M. A. Repina, T. Yu. Turovtseva, A. A. Katsap, O. S. Manikhas, N. P. Maslova, Ya. A. Kornilova, Ye. I. Baranova |
|---|---|
| Rok vydání: | 2005 |
| Předmět: | |
| Zdroj: | "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 11:24-28 |
| ISSN: | 2411-8524 1607-419X |
| Popis: | Objective to evaluate the efficacy and tolerability of fixed low-dose combination of permdopnl and indapamide and its co-administration with hormonal replacement therapy in women with postmenopausal hypertensive disease Materials and methods 63 women with grade 1-2 essential hypertension and postmenopausal syndrome were examined The patients were randomized to receive antihypertensive therapy with noliprel (Group 1) or its combination with hormonal replacement therapy (Group 2) The authors made blood pressure (BP) measurements by the Korotkoff method, 24-hour BP monitoring, echocardiography, studied the lipid spectrum, the plasma levels of glucose, creatinine, potassium, and uric acid, and determined life quality with the modified menopausal index Results A good subjective tolerability of therapy and a decrease in the menopausal index were noted in both groups The efficiency of antihypertensive therapy was 92 7% in Group 1 and 95 2% in Group 2 24-hour BP monitoring showed that the reduction in BP and pressure load was significantly higher in Group 2 than in Group 1 The therapy has no negative impact on metabolic parameters in both groups Conclusion Thus, noliprel is an effective drug in treating postmenopausal women with hypertensive disease Hormonal replacement therapy contributes to the higher antihypertensive effect of noliprel and exerts no effect on its metabolic neutrality |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|